XTX Topco Ltd Has $59,000 Stock Holdings in aTyr Pharma, Inc. (NASDAQ:ATYR)

XTX Topco Ltd boosted its position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 74.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,556 shares of the company’s stock after buying an additional 8,374 shares during the quarter. XTX Topco Ltd’s holdings in aTyr Pharma were worth $59,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Group One Trading LLC acquired a new position in shares of aTyr Pharma in the 4th quarter valued at $26,000. Raymond James Financial Inc. bought a new stake in shares of aTyr Pharma in the 4th quarter valued at $39,000. Two Sigma Advisers LP bought a new stake in shares of aTyr Pharma in the 4th quarter valued at $44,000. Y Intercept Hong Kong Ltd bought a new stake in shares of aTyr Pharma in the 1st quarter valued at $38,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter valued at $53,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Stock Performance

NASDAQ ATYR opened at $4.90 on Friday. The firm’s fifty day moving average price is $5.34 and its two-hundred day moving average price is $4.17. The stock has a market cap of $480.15 million, a PE ratio of -6.12 and a beta of 0.94. aTyr Pharma, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $7.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, equities analysts expect that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on ATYR shares. Wells Fargo & Company increased their target price on aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, June 20th. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of aTyr Pharma in a report on Wednesday, June 4th. Finally, Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, aTyr Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.25.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.